Overview

Perioperative Systemic Therapy in Patients Undergoing Surgery With HIPEC for Colon Cancer With Peritoneal Metastases: the CAIRO6 Study.

Status:
Not yet recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether cytoreductive surgery and HIPEC, combined with preoperative chemotherapy with targeted therapy and postoperative chemotherapy, results in improved overall survival compared to cytoreductive surgery and HIPEC alone in patients with peritoneal metastases of colorectal cancer. A survival increase of 15% is expected in the systemic therapy group. Furthermore, neoadjuvant systemic therapy may allow for better patient selection.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Catharina Ziekenhuis Eindhoven

Collaborator:

Hoffmann-La Roche

Treatments:

Bevacizumab
Capecitabine
Fluorouracil
Leucovorin
Oxaliplatin